GDC-0853

Product Name: GDC-0853
CAS No.: 1434048-34-6
Chemical Name: GDC-0853
Synonyms: GDC0853;CS-2241;EOS-61209;FENEBRUTINIB;GDC-0853;GDC 0853;GDC-0853 (RG7845);GDC-0853/Fenebrutinib;FENEBRUTINIB (GDC-0853);Fenebrutinib, 10 mM in DMSO;inhibit,Inhibitor,GDC0853,GDC 0853,Fenebrutinib,Btk,Bruton tyrosine kinase
CBNumber: CB33142405
Molecular Formula: C37H44N8O4
Formula Weight: 664.8
MOL File: 1434048-34-6.mol

More

Less

GDC-0853 Property

Boiling point:: 936.3±65.0 °C(Predicted)
Density: 1.42±0.1 g/cm3(Predicted)
storage temp.: Store at -20°C
solubility: DMF:20.0(Max Conc. mg/mL);30.08(Max Conc. mM)
DMSO:17.0(Max Conc. mg/mL);25.57(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.5(Max Conc. mM)
Ethanol:5.0(Max Conc. mg/mL);7.52(Max Conc. mM)
form: A crystalline solid
pka: 13.15±0.10(Predicted)
color: White to off-white
InChIKey: WNEODWDFDXWOLU-QHCPKHFHSA-N
SMILES: C12=CC3CC(C)(C)CC=3N1CCN(C1=NC=CC(C3C=C(NC4=NC=C(N5CCN(C6COC6)C[C@@H]5C)C=C4)C(=O)N(C)C=3)=C1CO)C2=O

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More

Less

N-Bromosuccinimide Price

Cayman Chemical

Product number: 21346
Product name: GDC-0853
Purity: ≥98%
Packaging: 1mg
Price: $39
Updated: 2024/03/01

Cayman Chemical

Product number: 21346
Product name: GDC-0853
Purity: ≥98%
Packaging: 5mg
Price: $180
Updated: 2024/03/01

Cayman Chemical

Product number: 21346
Product name: GDC-0853
Purity: ≥98%
Packaging: 10mg
Price: $340
Updated: 2024/03/01

Cayman Chemical

Product number: 21346
Product name: GDC-0853
Purity: ≥98%
Packaging: 25mg
Price: $647
Updated: 2023/06/20

TRC

Product number: F247550
Product name: Fenebrutinib
Packaging: 5mg
Price: $440
Updated: 2021/12/16

More

Less

GDC-0853 Chemical Properties,Usage,Production

Description

GDC-0853 is an orally bioavailable, selective, and reversible Bruton’s tyrosine kinase (BTK) inhibitor with IC₅₀s ranging from 2-9 nM for basophil activation, B cell receptor activation, and constitutive p-BTK activity in whole blood lysates. In rats, treatment for longer than 7 days leads to pancreatic toxicity but it does not occur in mice or dogs, even at higher doses. Formulations containing GDC-0853 were well-tolerated in Phase I clinical trials and are in additional clinical trials for rheumatoid arthritis, lupus erythematosus, lymphoma, and leukemia.

Uses

Fenebrutinib is a selective and reversible oral small-molecular BTK inhibitor for the treatment of rheumatoid arthritis and systemic lupus erythematosus.

in vivo

Fenebrutinib (GDC-0853) dose-dependently reduces ankle thickness following once (0.06, 0.25, 1, 4, and 16 mg/kg QD; orally) or twice (0.125, 0.5, and 2 mg/kg BID; orally) daily in female Lewis rats with developing collagen-induced arthritis^[2].
Fenebrutinib (0.2 mg/kg IV and 1.0 mg/kg PO; for rats) and (0.2 mg/kg IV and 0.5 mg/kg PO for dogs) demonstrates the half-lives (t_1/2s) of 2.2 and 3.8 h In rats, and dogs, respectively^[2].

Animal Model:	Female Lewis rats with developing collagen-induced arthritis (CIA)^[2]
Dosage:	0.06, 0.25, 1, 4, and 16 mg/kg once daily (QD); 0.125, 0.5, and 2 mg/kg twice daily (BID)
Administration:	Dosed orally; for 16 days
Result:	Dose-dependently reduced ankle thickness following QD and BID dosing regimens.

References

[1] JAMES J. CRAWFORD*. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development[J]. Journal of Medicinal Chemistry, 2018, 61 6: 2227-2245. DOI: 10.1021/acs.jmedchem.7b01712

GDC-0853 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

GDC-0853 Suppliers

China 100 India 2 United States 9 Global 111

Nantong Hanfang Biotechnology Co. , Ltd.

Tel: hanfangpharma@126.com; 18616537568
Email: hanfangpharma@126.com
Country: China
ProdList: 25801
Advantage: 58

Shanghai XingMo Biotechnology Co., Ltd.

Tel: +86 13524779951; 13524779951
Fax: QQ: 2075692521
Email: 2075692521@qq.com
Country: China
ProdList: 294
Advantage: 55

Chunchuang (Wuhan) Technology Co., Ltd

Tel: 15727060112
Email: yutianchun2007@126.com
Country: China
ProdList: 9856
Advantage: 58

Jiangsu Magic Biotechnology Co., Ltd

Tel: 13921770081
Email: svp01@magicbiotech.cn
Country: China
ProdList: 500
Advantage: 58

Xi’an Yino Biotechnology Co., Ltd.

Tel: 18809207782 18809207782
Email: 527644240@qq.com
Country: China
ProdList: 807
Advantage: 58

Nanjing Chemlin Chemical Co., Ltd

Tel: 025-83697070 13913916777
Fax: +86-25-83453306
Email: info@chemlin.com.cn
Country: China
ProdList: 16059
Advantage: 64

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4790
Advantage: 58

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7552
Advantage: 61

Shanghai Aladdin Bio-Chem Technology Co.,LTD

Tel: 400-6206333 13167063860
Fax: 021-50323701
Email: anhua.mao@aladdin-e.com
Country: China
ProdList: 26682
Advantage: 65

MedChemexpress LLC

Tel: 021-58955995
Fax: 609-228-5909
Email: sales@medchemexpress.cn
Country: United States
ProdList: 4861
Advantage: 58

More

Less

View Lastest Price from GDC-0853 manufacturers

Career Henan Chemical Co

Product: GDC-0853 1434048-34-6
Price: US $6.68/KG
Min. Order: 1KG
Purity: 97%-99%
Supply Ability: 1kg-1000kg
Release date: 2020-01-08

1434048-34-6, GDC-0853Related Search:

(S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one

GDC0853

EOS-61209

GDC-0853 (RG7845)

GDC-0853;GDC 0853

FENEBRUTINIB (GDC-0853)

FENEBRUTINIB

CS-2241

GDC-0853/Fenebrutinib

2H-Cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one, 2-[1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-

2-[1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one

inhibit,Inhibitor,GDC0853,GDC 0853,Fenebrutinib,Btk,Bruton tyrosine kinase

2-1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-5-(2S)-2-methyl-4-(3-oxetanyl)piperazin-1-ylpyridin-2-ylamino-6-oxo3,4'-bipyridin-2'-yl-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta4,5pyrrolo1,2-apyrazin-1(6H)-one

(S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one

Fenebrutinib, 10 mM in DMSO

(S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one

1434048-34-6